id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-P-7034-0007,FDA,FDA-2017-P-7034,Response Letter from FDA CDER to Jubilant Generics Limited,Other,Letter(s),2025-07-31T04:00:00Z,2025,7,2025-07-31T04:00:00Z,,2025-07-31T18:24:31Z,,0,0,09000064b8ebc5b5
FDA-2017-P-7034-0003,FDA,FDA-2017-P-7034,Exhibit 1 Orange Book Listing re Citizen Petition from Jubilant Generics Limited,Supporting & Related Material,Background Material,2017-12-29T05:00:00Z,2017,12,,,2018-01-02T16:53:20Z,,0,0,0900006482d84d72
FDA-2017-P-7034-0005,FDA,FDA-2017-P-7034,Exhibit 3 Proposed Product Draft Label re Citizen Petition from Jubilant Generics Limited,Supporting & Related Material,Background Material,2017-12-29T05:00:00Z,2017,12,,,2018-01-02T16:53:46Z,,0,0,0900006482d84d74
FDA-2017-P-7034-0001,FDA,FDA-2017-P-7034,Citizen Petition from Jubilant Generics Limited,Other,Citizen Petition,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,2018-06-28T03:59:59Z,2018-01-02T16:52:40Z,,0,0,0900006482d84d2a
FDA-2017-P-7034-0006,FDA,FDA-2017-P-7034,Exhibit 4 Valtrex Tablets 250 mg re Citizen Petition from Jubilant Generics Limited,Supporting & Related Material,Background Material,2017-12-29T05:00:00Z,2017,12,,,2018-01-02T16:53:57Z,,0,0,0900006482d84d75
FDA-2017-P-7034-0004,FDA,FDA-2017-P-7034,Exhibit 2 RLD Label re Citizen Petition from Jubilant Generics Limited,Supporting & Related Material,Background Material,2017-12-29T05:00:00Z,2017,12,,,2018-01-02T16:53:34Z,,0,0,0900006482d84d73
FDA-2017-P-7034-0002,FDA,FDA-2017-P-7034,Acknowledgment Letter from FDA DDM to Jubilant Generics Limited,Other,Acknowledgement Letter/Receipt,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2018-01-02T16:53:05Z,,0,0,0900006482d84d2c